Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant Consolidation and Maintenance for Multiple Myeloma

NCT04680468 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT04680468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04680468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant Consolidation and Maintenance for Multiple Myeloma
Lead sponsor
University of Pennsylvania
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 2, 2021
Completion date
November 1, 2028
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma